LT3007717T - Peptides with antagonistic activities against natural cxcr4 - Google Patents
Peptides with antagonistic activities against natural cxcr4Info
- Publication number
- LT3007717T LT3007717T LTEP14729370.8T LT14729370T LT3007717T LT 3007717 T LT3007717 T LT 3007717T LT 14729370 T LT14729370 T LT 14729370T LT 3007717 T LT3007717 T LT 3007717T
- Authority
- LT
- Lithuania
- Prior art keywords
- peptides
- activities against
- against natural
- antagonistic activities
- natural cxcr4
- Prior art date
Links
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13171718 | 2013-06-12 | ||
| PCT/EP2014/062252 WO2014198834A1 (en) | 2013-06-12 | 2014-06-12 | Peptides with antagonistic activities against natural cxcr4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3007717T true LT3007717T (en) | 2018-11-26 |
Family
ID=48578924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14729370.8T LT3007717T (en) | 2013-06-12 | 2014-06-12 | Peptides with antagonistic activities against natural cxcr4 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10294272B2 (en) |
| EP (1) | EP3007717B1 (en) |
| JP (1) | JP6667435B2 (en) |
| CN (2) | CN105530948B (en) |
| AU (1) | AU2014280191B2 (en) |
| CA (1) | CA2913387C (en) |
| CY (1) | CY1120843T1 (en) |
| DK (1) | DK3007717T3 (en) |
| ES (1) | ES2699576T3 (en) |
| HR (1) | HRP20181878T8 (en) |
| LT (1) | LT3007717T (en) |
| PL (1) | PL3007717T3 (en) |
| PT (1) | PT3007717T (en) |
| RS (1) | RS58164B1 (en) |
| RU (1) | RU2671708C2 (en) |
| SI (1) | SI3007717T1 (en) |
| SM (1) | SMT201800589T1 (en) |
| WO (1) | WO2014198834A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3473262A4 (en) * | 2016-06-16 | 2020-03-18 | The University Of Tokyo | PLEXIN LINK REGULATOR |
| JP7274228B2 (en) * | 2017-09-08 | 2023-05-16 | ネオペプ ファーマ ゲーエムベーハー ウント コンパニー カーゲー | Polypeptides for the treatment of diseases |
| CN113286806A (en) * | 2018-11-09 | 2021-08-20 | 尼欧派普制药有限两合公司 | Polypeptides for treatment of stress, immune response and stroke syndrome |
| EP3872084A1 (en) * | 2020-02-27 | 2021-09-01 | Universität Ulm | Epi-x4 based peptides and derivatives thereof |
| WO2023099725A1 (en) * | 2021-12-02 | 2023-06-08 | Pharis Biotec Gmbh | Pharmaceutical preparation containing a mixture of a natriuretic peptide (anp) and a peptidic inhibitor of the cxcr4 receptor |
| WO2024235986A1 (en) | 2023-05-15 | 2024-11-21 | Pharis Biotec Gmbh | Peptides for use in the treatment of sarcoma |
| EP4483892A1 (en) * | 2023-06-29 | 2025-01-01 | Pharis Biotec GmbH | Composition comprising lekti polypeptides for the treatment of disorders |
| EP4501348A1 (en) | 2023-08-02 | 2025-02-05 | Wolf-Georg Forssmann | Peptides for use in the improvement of well-being |
| EP4501347A1 (en) | 2023-08-02 | 2025-02-05 | Wolf-Georg Forssmann | Peptides for use in the treatment of central nervous system disorders |
| WO2025114560A1 (en) | 2023-12-01 | 2025-06-05 | Pharis Biotec Gmbh | Alb408-423 peptides for use in the treatment of cancer in combination with radiotherapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08511007A (en) | 1993-06-09 | 1996-11-19 | コノート ラボラトリーズ リミテッド | Tandem synthetic HIV-1 peptide |
| EP0967284A1 (en) * | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
| EP1171152A4 (en) * | 2000-02-03 | 2002-09-25 | Univ Jefferson | CXCR4 vMIP-II PEPTIDE ANTAGONISTS |
| US7390870B2 (en) * | 2001-07-03 | 2008-06-24 | Posco | Immune-enhancing peptides |
| US20040001993A1 (en) | 2002-06-28 | 2004-01-01 | Kinkelaar Mark R. | Gas diffusion layer for fuel cells |
| WO2004094465A2 (en) * | 2003-04-23 | 2004-11-04 | The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign | Synthetic molecules that mimic chemokines |
| AP2081A (en) * | 2004-06-18 | 2010-01-04 | Ipf Pharmaceuticals Gmbh | Oligomeric peptides and their use for the treatment of HIV infections |
| FR2877946B1 (en) | 2004-11-12 | 2011-02-11 | Commissariat Energie Atomique | MAUROCALCIN-DERIVED PEPTIDES FOR USE AS VECTORS FOR INTRACELLULAR ADDRESSING OF MOLECULES OF INTEREST |
| EP1986673A2 (en) * | 2006-02-13 | 2008-11-05 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health and Human Services | Methods and compositions related to ghs-r antagonists |
| US8288349B2 (en) | 2006-11-10 | 2012-10-16 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| DE102007030904A1 (en) * | 2007-07-03 | 2009-02-05 | Pharis Biotec Gmbh | Human circulating antiviral albumin fragment (ALB-408) and its use |
| SG172789A1 (en) * | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| EP2536756B1 (en) * | 2010-02-16 | 2018-04-25 | MedImmune, LLC | Hsa-related compositions and methods of use |
| JP2014510518A (en) | 2011-02-15 | 2014-05-01 | メディミューン，エルエルシー | HSA related compositions and methods of use |
| EP2564869A1 (en) * | 2011-09-02 | 2013-03-06 | Ceva Sante Animale | Synthetic capsid proteins and uses thereof |
-
2014
- 2014-06-12 SM SM20180589T patent/SMT201800589T1/en unknown
- 2014-06-12 AU AU2014280191A patent/AU2014280191B2/en not_active Ceased
- 2014-06-12 RU RU2015151872A patent/RU2671708C2/en active
- 2014-06-12 DK DK14729370.8T patent/DK3007717T3/en active
- 2014-06-12 CN CN201480033321.XA patent/CN105530948B/en active Active
- 2014-06-12 CN CN202010681852.7A patent/CN111875670A/en active Pending
- 2014-06-12 ES ES14729370T patent/ES2699576T3/en active Active
- 2014-06-12 PT PT14729370T patent/PT3007717T/en unknown
- 2014-06-12 SI SI201430966T patent/SI3007717T1/en unknown
- 2014-06-12 RS RS20181430A patent/RS58164B1/en unknown
- 2014-06-12 US US14/896,249 patent/US10294272B2/en active Active
- 2014-06-12 HR HRP20181878TT patent/HRP20181878T8/en unknown
- 2014-06-12 PL PL14729370T patent/PL3007717T3/en unknown
- 2014-06-12 WO PCT/EP2014/062252 patent/WO2014198834A1/en not_active Ceased
- 2014-06-12 CA CA2913387A patent/CA2913387C/en active Active
- 2014-06-12 LT LTEP14729370.8T patent/LT3007717T/en unknown
- 2014-06-12 EP EP14729370.8A patent/EP3007717B1/en active Active
- 2014-06-12 JP JP2016518492A patent/JP6667435B2/en active Active
-
2018
- 2018-11-09 CY CY181101190T patent/CY1120843T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105530948A (en) | 2016-04-27 |
| SI3007717T1 (en) | 2018-12-31 |
| WO2014198834A1 (en) | 2014-12-18 |
| PL3007717T3 (en) | 2018-12-31 |
| JP6667435B2 (en) | 2020-03-18 |
| US10294272B2 (en) | 2019-05-21 |
| CN105530948B (en) | 2023-05-26 |
| PT3007717T (en) | 2018-12-04 |
| ES2699576T3 (en) | 2019-02-11 |
| EP3007717B1 (en) | 2018-08-29 |
| AU2014280191A1 (en) | 2015-12-17 |
| DK3007717T3 (en) | 2019-01-02 |
| CN111875670A (en) | 2020-11-03 |
| CA2913387A1 (en) | 2014-12-18 |
| JP2016521716A (en) | 2016-07-25 |
| EP3007717A1 (en) | 2016-04-20 |
| HRP20181878T1 (en) | 2019-01-11 |
| CY1120843T1 (en) | 2019-12-11 |
| SMT201800589T1 (en) | 2019-01-11 |
| AU2014280191B2 (en) | 2018-10-11 |
| CA2913387C (en) | 2024-05-21 |
| HRP20181878T8 (en) | 2019-03-08 |
| RU2015151872A (en) | 2017-07-17 |
| RU2671708C2 (en) | 2018-11-06 |
| RS58164B1 (en) | 2019-03-29 |
| US20160122389A1 (en) | 2016-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2508037B (en) | Chair | |
| AU355185S (en) | Chair | |
| ZA201505966B (en) | Peptides and compositions | |
| SMT201800589T1 (en) | Peptides with antagonistic activities against natural cxcr4 | |
| GB201305277D0 (en) | Novel combination and use | |
| AU351025S (en) | Chair | |
| GB2520812B (en) | Lift-recliner chair | |
| PT2855506T (en) | Peptide and the use thereof | |
| LT3087092T (en) | Antimicrobial peptide and uses thereof | |
| PL2910131T3 (en) | Anti-fatigue composition and use thereof | |
| GB201307989D0 (en) | Novel combinations and use | |
| GB201308122D0 (en) | Chair | |
| AU353456S (en) | Hammock | |
| GB201313405D0 (en) | Hammock | |
| AU352786S (en) | Chair | |
| AU352787S (en) | Chair | |
| AU352785S (en) | Chair | |
| AU352853S (en) | Chair | |
| PH32013001227S1 (en) | Chair | |
| PH32013001222S1 (en) | Chair | |
| PH32013001223S1 (en) | Chair | |
| PH32013001221S1 (en) | Chair | |
| AU350353S (en) | Chair | |
| AU350354S (en) | Chair | |
| AU350355S (en) | Chair |